Evolus, Inc. (EOLS)
| Market Cap | 469.54M |
| Revenue (ttm) | 301.79M |
| Net Income (ttm) | -43.42M |
| Shares Out | 65.85M |
| EPS (ttm) | -0.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,075,327 |
| Open | 7.15 |
| Previous Close | 7.15 |
| Day's Range | 6.96 - 7.32 |
| 52-Week Range | 3.86 - 10.20 |
| Beta | 1.33 |
| Analysts | Strong Buy |
| Price Target | 14.67 (+105.75%) |
| Earnings Date | Aug 4, 2026 |
About EOLS
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newpo... [Read more]
Financial Performance
In 2025, Evolus's revenue was $297.18 million, an increase of 11.61% compared to the previous year's $266.27 million. Losses were -$51.64 million, 2.42% more than in 2024.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for EOLS stock is "Strong Buy." The 12-month stock price target is $14.67, which is an increase of 105.75% from the latest price.
News
Evolus Transcript: AGM 2026
The meeting confirmed quorum, presented three proposals, and all were approved by shareholders. No questions were raised during the Q&A, and the meeting was conducted virtually with proper notice.
Evolus files $250M mixed securities shelf
16:47 EDT Evolus (EOLS) files $250M mixed securities shelf
Evolus Registration statement: Registration filing
Evolus filed a registration statement on June 5, 2026, providing details about a securities offering with the SEC.
Evolus management to meet virtually with BTIG
Medical Technology Analyst Eiber holds a Virtual Meeting with Management on June 11 hosted by BTIG.
Evolus Transcript: Jefferies Global Healthcare Conference 2026
The company has evolved into a diversified aesthetics platform, expanding internationally and leveraging digital efficiencies for scalable growth. Product innovation, especially in HA injectables, and strong clinic partnerships drive market share gains. GLP-1 trends and a robust pipeline support long-term growth and profitability.
Evolus to Participate in The Jefferies Global Healthcare Conference
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its man...
Evolus announces commercial launch of Estyme in Europe
Evolus (EOLS) announced that the commercial launch of Estyme, its injectable hyaluronic acid gel collection in Europe, is scheduled for May 16th, marking the company’s entry into the international der...
Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the co...
Evolus Earnings Call Transcript: Q1 2026
Q1 saw 7% revenue growth, positive Adjusted EBITDA, and strong Jeuveau performance, with robust international expansion and a resilient U.S. market. Guidance for 2026 and long-term outlook remain unchanged, despite tariff risks and evolving competition.
Evolus Earnings release: Q1 2026
Evolus released its Q1 2026 earnings on May 4, 2026, summarizing the period's financial results.
Evolus Slides: Q1 2026
Evolus has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 4, 2026.
Evolus Quarterly report: Q1 2026
Evolus has published its Q1 2026 quarterly earnings report on May 4, 2026.
Evolus reports Q1 EPS (16c), consensus (12c)
Reports Q1 revenue $73.1M, consensus $72.17M. “We started 2026 with a second consecutive quarter of positive Adjusted EBITDA, delivering profitability in what is seasonally our lowest revenue quarter,...
Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financi...
Weight-loss revolution sparks new appetite for aesthetics firms
Aesthetic firms are betting that a growing pool of patients experiencing loose skin and facial volume loss from GLP-1 obesity drugs will fuel a new wave of demand, as the sector heads into first-quart...
Evolus Slides: Investor presentation
Evolus has posted slides in relation to its latest quarterly earnings report, which was published on May 4, 2026.
Evolus Proxy statement: Proxy filing
Evolus filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Evolus Proxy statement: Proxy filing
Evolus filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Evolus Transcript: 25th Annual Needham Virtual Healthcare Conference
Mid-teens market share and double-digit growth were achieved in 2025, with international expansion and a new HA filler, Evolysse, strengthening the portfolio. The company expects continued growth, stable pricing, and profitability in 2026, with Sculpt poised as a key future driver.
Evolus to Report First Quarter Financial Results on May 4, 2026
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will repor...
Evolus Slides: Investor presentation
Evolus has posted slides in relation to its latest quarterly earnings report, which was published on April 10, 2026.
Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its man...
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS) a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant during Mar...
Evolus Transcript: Leerink Global Healthcare Conference 2026
Toxin market recovery began in late 2023, with filler recovery lagging but showing positive signs, especially in Europe. Product differentiation, portfolio bundling, and a robust loyalty program are driving growth, with 2026 revenue guidance at $327M-$337M and international expansion underway.
Evolus Earnings Call Transcript: Q4 2025
Delivered 12% revenue growth in 2025 and achieved Q4 profitability despite a rare market decline. Guidance for 2026 targets 10–13% revenue growth, stable margins, and sustained profitability, with new product launches and international expansion supporting future growth.